|Primary Industry:||Health & Medical Devices|
|Executive Summary:||GenePOC is a start-up of the Centre de recherche en infectiologie (CRI) of Université Laval in Québec City. The CRI is the largest infectious diseases research center in Canada. A previous CRI start-up, Infectio Diagnostics, has put on the market the first two FDA approved rapid real-time PCR assays: the IDI-Strep B™ and the IDI-MRSA™. GenePOC was created to undertake technology transfer of CRI’s most recent rapid automated Genomics Point-of-Care tests (GPOCTs).
GenePOC’s technology platforms in sample preparation and microfluidics have been developed in partnership with researchers from Université Laval, University of California Irvine and National Research Council of Canada. These partners and others agreed to share the IP required for GenePOC’s pipeline of products.
GenePOC is seeking partners to co-finance the development and commercialisation of its Viral Respiratory Tract Infection GPOCT. GenePOC is also looking for R&D partnerships to increase the applications of its rapid diagnostic technology platform. Healthcare, water, food, animal and cosmetic industries might benefit from GenePOC’s rapid diagnostic platform.
Québec is a booming centre in biotechnology and was recognized as the best city to do business in Canada (Canadian Business magazine).|
|Venture is:||Seed Level|